Azitra, Inc.(AZTR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.7M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AZTR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Azitra, Inc. (AZTR), a Healthcare sector company. AZTR is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), Azitra, Inc. reports net income of $-3.9M, free cash flow of $-2.5M. Top institutional holders of AZTR by reported 13-F value include GEODE CAPITAL MANAGEMENT,, UBS Group AG, StoneX Group, based on the most recent SEC filings. AZTR trades on the NYSE exchange and files with the SEC under CIK 1701478. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AZTR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Azitra, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-3.9M
Free Cash Flow
Q1 2026
$-2.5M
AI Insight: AZTR Financial Trends
Azitra remains pre-revenue with persistent operating losses and equity volatility; latest quarter saw net loss widen to $4M.
• Revenue has remained at or near $0M across all eight quarters through Q1 2026, indicating no commercial progress.
• Operating cash burn averaged $2.6M per quarter; Q1 2026 maintained $2M outflow despite widening operating loss.
• Equity recovered to $10M in Q1 2026 from $2M low in Q2–Q3 2025, likely from capital raise.
⚠ Net loss accelerated to $4M in Q1 2026 from $2–3M range in prior quarters—first deterioration in loss magnitude.
⚠ Cash runway unclear: equity gains suggest fundraising, but sustained $2–3M quarterly burn requires ongoing capital access.
AI Insight: AZTR Ratio Trends
Azitra remains deeply unprofitable with negative ROE of -149.9% in Q1 2026, showing no clear path to profitability.
• ROE deteriorated to -149.9% in Q1 2026 from -50.1% in Q3 2024, indicating worsening shareholder value destruction.
• Data sparse across most profitability metrics (OpMargin, NPM, ROIC, D/E) — insufficient visibility into operational trends.
⚠ Consecutive quarters of negative ROE and ROA signal persistent unprofitability; recovery timeline remains unclear.
⚠ TTM ROE of -112.7% and ROA of -97.4% reflect cumulative losses over trailing twelve months.
Get alerted when AZTR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Azitra, Inc. including:
Top Institutional Holders of AZTR
GEODE CAPITAL MANAGEMENT, LLC
$110.0K469,878 shUBS Group AG
$7.1K30,205 shStoneX Group Inc.
$5.3K22,464 shTower Research Capital LLC (TRC)
$3.5K15,085 shCITIGROUP INC
$399.001,705 shDauntless Investment Group, LLC
$234.001,000 shFMR LLC
$35.00150 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $110.0K | 469,878 |
| UBS Group AG | $7.1K | 30,205 |
| StoneX Group Inc. | $5.3K | 22,464 |
| Tower Research Capital LLC (TRC) | $3.5K | 15,085 |
| CITIGROUP INC | $399.00 | 1,705 |
| Dauntless Investment Group, LLC | $234.00 | 1,000 |
| FMR LLC | $35.00 | 150 |
More Healthcare Companies
View all Healthcare →Put AZTR on your watchlist
Track score changes the day Azitra, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AZTR a good stock to buy?
13F Pro's AI-powered analysis of Azitra, Inc. (AZTR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AZTR are available on the AZTR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AZTR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AZTR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Azitra, Inc.'s investment landscape.